-
奧吩達(dá)唑
- names:
Oxfendazole
- CAS號(hào):
53716-50-0
MDL Number: MFCD00801063 - MF(分子式): C15H13N3O3S MW(分子量): 315.35
- EINECS:258-714-5 Reaxys Number:53716-50-0
- Pubchem ID:37316 Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價(jià)格 (¥) | 現(xiàn)價(jià)(¥) | 特價(jià)(¥) | 庫(kù)存描述 | 數(shù)量 | 總計(jì) (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM000788-25g | 25g | 98% | ¥ 415.00 | ¥ 415.00 | 298 | 1-2days | ¥ 0.00 | |
| YZM000788-5g | 5g | 98% | ¥ 152.00 | ¥ 152.00 | 108 | 1-2days | ¥ 0.00 | |
| YZM000788-1g | 1g | 98% | ¥ 98.00 | ¥ 98.00 | 68 | 1-2days | ¥ 0.00 |
- 大包裝詢價(jià) 提供各種包裝,敬請(qǐng)垂詢
- 收藏商品 商品點(diǎn)評(píng) 加入購(gòu)物車 立即購(gòu)買
| 中文別名 | 奧吩達(dá)唑(Oxfendazole,53716-50-0)奧酚噠唑、奧芬噠唑、苯亞砜咪酯、苯硫氧咪唑,是苯硫咪唑的亞砜形態(tài) |
| 英文別名 | Oxfendazole(奧吩達(dá)唑,53716-50-0) |
| CAS號(hào) | 53716-50-0 |
| Inchi | InChI=1S/C15H13N3O3S/c1-21-15(19)18-14-16-12-8-7-11(9-13(12)17-14)22(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,16,17,18,19) |
| InchiKey | BEZZFPOZAYTVHN-UHFFFAOYSA-N |
| 分子式 Formula | C15H13N3O3S |
| 分子量 Molecular Weight | 315.35 |
| 溶解度Solubility | 生物體外In Vitro:DMSO溶解度50 mg/mL(158.55 mM;Need ultrasonic)H2O : 0.67 mg/mL(2.12 mM;Need ultrasonic) |
| 性狀 | 固體粉末,Power |
| 儲(chǔ)藏條件 Storage conditions | -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
| 生物 | 測(cè)試類型 | 路線 | 報(bào)告劑量(標(biāo)準(zhǔn)化劑量) | 影響 | 參考 |
| dog | LD50 | unreported | > 1600mg/kg (1600mg/kg) | Journal of Medicinal Chemistry. Vol. 18, Pg. 1164, 1975. | |
| mouse | LD50 | unreported | > 6400mg/kg (6400mg/kg) | Journal of Medicinal Chemistry. Vol. 18, Pg. 1164, 1975. | |
| rat | LD50 | unreported | > 6400mg/kg (6400mg/kg) | Journal of Medicinal Chemistry. Vol. 18, Pg. 1164, 1975. |
奧吩達(dá)唑(Oxfendazole,53716-50-0)理性質(zhì):
| 物理屬性 | 值 | 單位 | 溫度(攝氏度) | 資源 |
| Melting Point | 253 dec | deg C | EXP | |
| log P (octanol-water) | 1.630 | (none) | EST | |
| Atmospheric OH Rate Constant | 1.07E-10 | cm3/molecule-sec | 25 | EST |
Oxfendazole(奧吩達(dá)唑,53716-50-0)實(shí)驗(yàn)注意事項(xiàng):
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡,穿戴防護(hù)服和口罩,佩戴手套,避免與皮膚接觸。
2.實(shí)驗(yàn)過(guò)程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生,必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對(duì)實(shí)驗(yàn)人員造成傷害
3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲(chǔ),并交于專業(yè)生物廢氣物處理公司處理,以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:奧吩達(dá)唑MSDS,奧吩達(dá)唑蒸汽壓,奧吩達(dá)唑合成,奧吩達(dá)唑標(biāo)準(zhǔn),奧吩達(dá)唑應(yīng)用,奧吩達(dá)唑合成,奧吩達(dá)唑沸點(diǎn),奧吩達(dá)唑閃點(diǎn),奧吩達(dá)唑用途,奧吩達(dá)唑溶解度,奧吩達(dá)唑價(jià)格,奧吩達(dá)唑作用,奧吩達(dá)唑結(jié)構(gòu)式,奧吩達(dá)唑用處,奧吩達(dá)唑毒理性質(zhì),奧吩達(dá)唑物理性質(zhì)
| 產(chǎn)品說(shuō)明 | 奧吩達(dá)唑(Oxfendazole,53716-50-0)屬于稱為苯并咪唑的有機(jī)化合物。 奧吩達(dá)唑含有與咪唑環(huán)稠合的苯環(huán)的有機(jī)化合物 |
| Introduction | Oxfendazole(奧吩達(dá)唑,53716-50-0)Belong to the organic compound called benzimidazole. Ondazole is an organic compound containing a benzene ring fused to an imidazole ring |
| Application1 | |
| Application2 | |
| Application3 |
| 警示圖 | |
| 危險(xiǎn)性 | warning |
| 危險(xiǎn)性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對(duì)身體有害 |
| 安全防護(hù) | P264處理后徹底清洗+P280戴防護(hù)手套/穿防護(hù)服/戴防護(hù)眼罩/戴防護(hù)面具+P305如果進(jìn)入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡(如果有)并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護(hù)理 |
| 備注 | 實(shí)驗(yàn)過(guò)程中防止吸入、食入,做好安全防護(hù) |
| Gene expression analyses of the liver in rats treated with oxfendazole Archives of Toxicology 2007/PMID: 17340121 |
| Immunohistochemical analyses at the late stage of tumor promotion by oxfendazole in a rat hepatocarcinogenesis model Archives of Toxicology 2010/PMID: 20502879 |
| Involvement of oxidative stress in hepatocellular tumor-promoting activity of oxfendazole in rats Archives of Toxicology 2008/PMID: 18754104 |
| Antioxidant enzymatically modified isoquercitrin or melatonin supplementation reduces oxidative stress-mediated hepatocellular tumor promotion of oxfendazole in rats Archives of Toxicol/PMID: 20033131 |
| Efficacy of oxfendazole and fenbendazole against tortoise (Testudo hermanni) oxyurids Parasitology Research 2006/PMID: 17120044 |
Study (1991 to 2001) of drug-resistant Population B small strongyles in critical tests in horses in Kentucky at the termination of a 40-year investigation
Abstract:
Population B, drug-resistant small strongyles have been studied in naturally infected horses in Kentucky for more than 40 years. These parasites first were found to be resistant to phenothiazine (PTZ) and thiabendazole (TBZ), later to other parasiticides. Studies have been on evaluation of antiparasitic efficacy of several compounds, especially the benzimidazoles, against Population B small strongyles in clinical (field) tests (1959-1983) on the commercial farm of origin and in clinical and critical tests (1966-2001) at the University of Kentucky (UK) research farm. Research on these nematodes through 1990 has been published. The current paper presents data on efficacies of various anthelmintics (mostly TBZ) against these and other internal parasites in critical tests done between 1991 and 2001. These were the last critical tests in the UK horses; the entire herd was terminated in 2005. Population B small strongyles were established in horses on a pasture at the UK research farm on Old Lot 4 in 1966, and a satellite of this group was relocated to Field 24 in 1987. The last treatment of any of the horses in clinical tests on pasture was 22 years for Old Lot 4 (mostly benzimidazoles) and 5 years for Field 24 (TBZ) before the last critical test in 2001. Antiparasitic compounds (all paste formulations) administered orally in critical tests (n = 36) reported in this paper were TBZ (@ 44 mg/kg), pyrantel pamoate (PRT @ 6.6 mg base/kg), PTZ (@ 55 mg/kg), fenbendazole (FBZ @ 5 mg/kg), oxfendazole (OFZ @ 10 mg/kg), and oxibendazole (OBZ @ 10 mg/kg). The drug given and number of horses treated from Old Lot 4 were TBZ (18), PRT (3), PTZ (2), FBZ (2), OFZ (1), and OBZ (1) and from Field 24 were OFZ (1) and TBZ (8). Removal of small strongyles in Old Lot 4 was excellent for PRT, OFZ, and OBZ but much less for TBZ, PTZ, and FBZ. For the 16 species present in this lot, removal by TBZ was lowest for seven species (Coronocyclus (Cor.) coronatus, Cyathostomum (Cya.) catinatum, Cylicocyclus (Cyc.) nassatus, Cylicostephanus (Cys.) calicatus, Cylicostephanus goldi, Cylicostephanus longibursatus, and Cylicostephanus minutus). Of these seven species, lowest activity was found for five by PTZ and FBZ. One of the five resistant species was different for each of these two drugs. In Field 24, efficacy against small strongyles was excellent for the one foal treated with OFZ early (1992) in the study. TBZ initially had higher activity than in later years. Of the 12 small strongyle species present in this field, TBZ activity throughout the study was, in general, low for Cor. coronatus, Cys. goldi, and Cys. longibursatus, but it declined more or less progressively for Cya. catinatum, Cylicocyclus leptostomus, Cyc. nassatus, and Cys. calicatus over the study period. Cys. minutus were not present in high enough numbers to evaluate drug efficacy. Overall activity of TBZ on the group of small strongyles did not change; that is, susceptibility did not increase over time in Old Lot 4 where these parasites were not exposed to a benzimidazole for many years. However, in Field 24, where additional TBZ pressure was put on these parasites, efficacy not only did not increase but it decreased. From the data for small strongyles in the two groups of foals, eight species were considered benzimidazole resistant in varying degrees (most research on TBZ). Data on prevalence and drug activity on other internal parasite species besides small strongyles also are given.
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色,是通過(guò)細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi),細(xì)胞在玻片上生長(zhǎng),主要用于組織學(xué),免疫組織化學(xué)...
2020/7/20 22:04:33

提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有:異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26

9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55

Waxfilm 實(shí)驗(yàn)室封口膜:技術(shù)與國(guó)際市場(chǎng)的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域,封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來(lái),Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40

Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國(guó)產(chǎn)技術(shù)突破和品牌突破,是生物領(lǐng)域中國(guó)技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07

各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合:目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接,每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09

新一代微流控鍵合解決方案
微流控鍵合解決方案:微流控芯片制造的一個(gè)重要環(huán)節(jié),也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是:微流控...
2023/7/27 12:44:28
驗(yàn)動(dòng)物圖.png)
熒光素鉀鹽使用說(shuō)明
D-熒光素鉀鹽(K+)設(shè)計(jì)用于體外和體內(nèi)生物發(fā)光測(cè)定。D-熒光素的質(zhì)量和純度對(duì)于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11

如何選BSA(牛血清白蛋白)
如何選BSA(牛血清白蛋白):牛血清白蛋白(BSA)有多種形式,如何選擇適合自己的牛血清白蛋白(BSA)是一...
2023/2/14 13:09:18

牛血清白蛋白(BSA)常見問(wèn)題
牛血清白蛋白(BSA)常見問(wèn)題:牛血清白蛋白(BSA)在實(shí)驗(yàn)室中是通用的,可用于蛋白質(zhì)印跡、細(xì)胞組織培養(yǎng)、P...
2022/10/19 9:39:51



購(gòu)物車 


